The data collected will be utilized to analyze the impact of exposures such as air pollution, excessive heat, water pollution and “forever chemicals” as well as behavioral and inherited factors on human health.

The V Foundation for Cancer Research has awarded a $600,000 grant to Tae Kon Kim, MD, PhD, assistant professor of Medicine (Hematology and Oncology). Kim and colleagues will study whether this protein hinders the ability of the immune system to fight MDS and whether it can be blocked to treat MDS.

Russell Rothman, MD, MPP (Internal Medicine and Public Health), is first author of a study recently published in JAMA Network Open that found montelukast, a drug commonly prescribed to prevent and treat asthma and exercise-induced bronchoconstriction, does not speed recovery from symptoms of mild to moderate COVID-19.

Anna Person, MD, professor of Medicine in the Division of Infectious Diseases, is the recipient of the 2024 Clinical Teacher Award from the Infectious Diseases Society of America (IDSA).

Danielle Dean, PhD, assistant professor of Medicine in the Division of Diabetes, Endocrinology and Metabolism, has received the Robert L. Sorenson Young Investigator Award from the Midwest Islet Club (MIC) in recognition of her research excellence and innovation in the field of islet research.

In this new position Cathy Eng, MD (Hematology and Oncology), the David H. Johnson Professor of Surgical and Medical Oncology, will elevate Vanderbilt-Ingram’s profile locally, regionally, nationally and internationally through stakeholder engagement, programmatic development and targeted marketing.

Interim results are promising from on ongoing phase 1 clinical trial testing an allogeneic or “off-the-shelf” chimeric antigen receptor Tcell (CAR T) therapy for patients with multiple myeloma who have not responded to existing treatments or who have relapsed.

Kimberlyn Ellis, a graduate student in the Training Program in Human Genetics, has been selected as the 2024 Vanderbilt Prize Student Scholar.

A cancer vaccine that had little success in clinical trials for patients with advanced tumors could potentially have efficacy if administered earlier in the treatment cycle, according to a study from Vanderbilt researchers.

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.